Erratum: Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial (The Lancet (2018) 392(10154) (1207–1216), (S0140673617328441) (10.1016/S0140-6736(17)32844-1));Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial

The Lancet

Volumn 392, Issue 10154, 2018, Pages 1207-1216

  Opoku, Nicholas O ^a   Bakajika, Didier K ^b   Kanza, Eric M ^c   Howard, Hayford ^d   Mambandu, Germain L ^e   Nyathirombo, Amos ^f   Nigo, Maurice M ^g   Kasonia, Kambale ^c   Masembe, Safari L ^c   Mumbere, Mupenzi ^c   Kataliko, Kambale ^c   Larbelee, Jemmah P ^h   Kpawor, Mawolo ⁱ   Bolay, Kpehe M ⁱ   Bolay, Fatorma ⁱ   Asare, Sampson ^j   Attah, Simon K ^k   Olipoh, George ^l   Vaillant, Michel ^m   Halleux, Christine M ⁿ   Kuesel, Annette C ⁿ   more..

^a UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Ghana)

^b WHO/AFRO   (Congo)

^c Université Catholique du Graben UCG   (Democratic Republic Congo)

^d Kolahun Hospital   (Liberia)

^e Ministère Provincial de la Santé   (Democratic Republic Congo)

^f GULU UNIVERSITY   (Uganda)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h Eye Care Services   (Liberia)

ⁱ Liberia Institute for Biomedical Research (LIBR)   (Liberia)

^j SOUTH DAKOTA STATE UNIVERSITY   (United States)

^k UNIVERSITY OF GHANA   (Ghana)

^l GHANA INSTITUTE OF MANAGEMENT AND PUBLIC ADMINISTRATION   (Ghana)

^m LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

ⁿ WORLD HEALTH ORGANIZATION   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IVERMECTIN; MOXIDECTIN; ANTHELMINTIC AGENT; MACROLIDE; MILBEMYCIN;

ADOLESCENT; ADULT; ARTICLE; BLURRED VISION; CHILD; CONJUNCTIVITIS; CONTROLLED STUDY; DEMOCRATIC REPUBLIC CONGO; DENSITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPIPHORA; EYE DISCOMFORT; EYE PAIN; EYE SWELLING; FEMALE; FOLLOW UP; GHANA; HUMAN; HUMAN CELL; LIBERIA; LONGITUDINAL STUDY; LYMPHATIC FILARIASIS; MAJOR CLINICAL STUDY; MALE; MICROFILARIA (NEMATODE LARVA); MULTICENTER STUDY; NONHUMAN; OCULAR ONCHOCERCIASIS; OCULAR PRURITUS; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; ORTHOSTATIC HYPOTENSION; PARALLEL DESIGN; PARASITE CLEARANCE; PARASITE TRANSMISSION; PHASE 3 CLINICAL TRIAL; PHOTOPHOBIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SUPERIORITY TRIAL; TABLET; ANIMAL; CLINICAL TRIAL; DRUG EFFECT; ENDEMIC DISEASE; PARASITE LOAD; PARASITOLOGY; SKIN;

ADOLESCENT; ANIMALS; ANTHELMINTICS; DEMOCRATIC REPUBLIC OF THE CONGO; DOUBLE-BLIND METHOD; ENDEMIC DISEASES; FEMALE; GHANA; HUMANS; IVERMECTIN; LIBERIA; MACROLIDES; MALE; MICROFILARIAE; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; PARASITE LOAD; SKIN;

EID: 85040638593     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)32403-6     Document Type: Erratum

References (29)

1. Remme, JHF, Boatin, B, Boussinesq, M, Helminthic diseases: onchocerciasis and loiasis. Quah, SR, Cockerham, WC, (eds.) The international encyclopedia of public health, 2nd edn., 2017, Elsevier, Oxford, 576–587.
2. Basanez, MG, Pion, SD, Boakes, E, Filipe, JA, Churcher, TS, Boussinesq, M, Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect Dis 8 (2008), 310–322.
3. Center for Disease Control and Prevention. Progress toward elimination of onchocerciasis in the Americas 1993–2012. MMWR Morb Mortal Wkly Rep 62 (2013), 405–408.
4. Botto, C, Basanez, MG, Escalona, M, et al. Evidence of suppression of onchocerciasis transmission in the Venezuelan Amazonian focus. Parasit Vectors 9 (2016), 40–58.
5. Tekle, AH, Zoure, HG, Noma, M, et al. Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results. Infect Dis Poverty 5 (2016), 66–91.
6. African Programme for Onchocerciasis Control. Strategic options and alternative treatment strategies for accelerating onchocerciasis elimination in Africa. http://who.int/apoc/ATS_Report_2015.12.pdf, 2015 (accessed Aug 23, 2017).
7. Kuesel, AC, Research for new drugs for elimination of onchocerciasis in Africa. Int J Parasitol Drugs Drug Resist 6 (2016), 272–286.
8. Prichard, R, Menez, C, Lespine, A, Moxidectin and the avermectins: consanguinity but not identity. Int J Parasitol Drugs Drug Resist 2 (2012), 134–153.
9. Cotreau, MM, Warren, S, Ryan, JL, et al. The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans. J Clin Pharmacol 43 (2003), 1108–1115.
10. Korth-Bradley, JM, Parks, V, Chalon, S, et al. Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women. Antimicrob Agents Chemother 55 (2011), 5200–5204.
11. Korth-Bradley, JM, Parks, V, Chalon, S, et al. The effect of a high-fat breakfast on the pharmacokinetics of moxidectin in healthy male subjects: a randomized phase I trial. Am J Trop Med Hyg 86 (2012), 122–125.
12. Korth-Bradley, JM, Parks, V, Patat, A, Matschke, K, Mayer, P, Fleckenstein, L, Relative bioavailability of liquid and tablet formulations of the antiparasitic moxidectin. Clin Pharmacol Drug Dev 1 (2012), 32–37.
13. Korth-Bradley, JM, Parks, V, Wagner, F, et al. Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects. Clin Pharmacol Drug Dev 3 (2014), 151–157.
14. Awadzi, K, Opoku, NO, Attah, SK, Lazdins-Helds, J, Kuesel, AC, A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis, 8, 2014, e2953.
15. Awadzi, K, The chemotherapy of onchocerciasis II. Quantitation of the clinical reaction to microfilaricides. Ann Trop Med Parasitol 74 (1980), 189–197.
16. Hero, M, Bird, AC, Awadzi, K, Quantification of the ocular reactions to microfilaricides in the chemotherapy of onchocerciasis. Eye (Lond) 6 (1992), 93–96.
17. Awadzi, K, Opoku, NO, Addy, ET, Quartey, BT, The chemotherapy of onchocerciasis. XIX: the clinical and laboratory tolerance of high dose ivermectin. Trop Med Parasitol 46 (1995), 131–137.
18. DeSole, G, Awadzi, K, Remme, J, et al. A community trial of ivermectin in the onchocerciasis focus of Asubende, Ghana. II. Adverse reactions. Trop Med Parasitol 40 (1989), 375–382.
19. DeSole, G, Remme, J, Awadzi, K, et al. Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials. Bull World Health Organ 67 (1989), 707–719.
20. African Programme for Onchocerciasis Control. African programme for onchocerciasis control: progress report, 2014–2015. Wkly Epidemiol Rec 90 (2015), 661–674.
21. Turner, HC, Walker, M, Attah, SK, et al. The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the phase II clinical trial data. Parasit Vectors 8 (2015), 167–179.
22. D'Ambrosio, MV, Bakalar, M, Bennuru, S, et al. Point-of-care quantification of blood-borne filarial parasites with a mobile phone microscope. Sci Transl Med, 7, 2015, 286re4.
23. Awadzi, K, Boakye, DA, Edwards, G, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 98 (2004), 231–249.
24. Awadzi, K, Attah, SK, Addy, ET, et al. Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 98 (2004), 359–370.
25. Osei-Atweneboana, MY, Eng, JK, Boakye, DA, Gyapong, JO, Prichard, RK, Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet 369 (2007), 2021–2029.
26. Osei-Atweneboana, MY, Awadzi, K, Attah, SK, Boakye, DA, Gyapong, JO, Prichard, RK, Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus. PLoS Negl Trop Dis, 5, 2011, e998.
27. Pion, SD, Nana-Djeunga, HC, Kamgno, J, et al. Dynamics of Onchocerca volvulus microfilarial densities after ivermectin treatment in an ivermectin-naive and a multiply treated population from Cameroon. PLoS Negl Trop Dis, 7, 2013, e2084.
28. Frempong, KK, Walker, M, Cheke, RA, et al. Does increasing treatment frequency address suboptimal responses to ivermectin for the control and elimination of river blindness?. Clin Infect Dis 62 (2016), 1338–1347.
29. Mounsey, KE, Bernigaud, C, Chosidow, O, McCarthy, JS, Prospects for moxidectin as a new oral treatment for human scabies. PLoS Negl Trop Dis, 10, 2016, e0004389.